SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K
Annual Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
FOR THE FISCAL YEAR ENDED COMMISSION FILE NUMBER
December 31, 1995 0-12248
Daxor Corporation
(Exact name of Registrant as specified in its charter)
New York 13-2682108
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification Number)
350 Fifth Avenue
Suite 7120
New York, New York 10118
(Address of principal executive offices) (Zip Code)
Registrant's telephone number: (212) 244-0555
Securities registered pursuant to Section 12(b) of the Act:
Common Shares, $.01 par value
(Title of Class)
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark whether Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months and (2) has been subject to such filing
requirements for the past 90 days.
Yes (X) No ( )
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-X is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
form 10-K. [ ]
As at March 28, 1996, the aggregate market value of the voting stock held by
non-affiliates of the Registrant was $ 12,340,640. The market value of Common
Stock of the Registrant, par value $.01 per share, was computed by reference to
the closing price of one share on such date, as reported by the American Stock
Exchange, which was $ 8.00.
The number of shares outstanding of the Registrant's Common Stock,
par value $.01 per share, as of March 28, 1996: 4,722,709 shares.
Documents incorporated by reference: The information required by Part III
is incorporated by reference from the proxy statement for the 1995 Annual
Meeting of Shareholders.
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities and
Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereto duly authorized.
DAXOR CORPORATION
by: /s/ Joseph Feldschuh
Joseph Feldschuh, M.D.
President and Chief
Executive Officer
Chairman of the Board
Dated: March 30, 1996
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated.
Signature Title Date
/s/ Joseph Feldschuh President and Director March 30, 1996
Joseph Feldschuh, M.D. (Principal Executive Officer)
/s/ Octavia Atanasiu Corporate Treasurer March 30, 1996
Octavia Atanasiu Accounting Supervisor
(Principal Financial Officer)
/s/ Stephen M. Moss Director March 30, 1996
Stephen M. Moss, PhD
/s/ Veronica Schwendemann Director March 30, 1996
Veronica Schwendemann
/s/ James Lombard Director March 30, 1996
James Lombard
/s/ Martin Wolpoff Director March 30, 1996
Martin Wolpoff
Board of Directors:
Name Title
Dr. Joseph Feldschuh Chairman, President, & CEO
Stephen Moss Director
James Lombard Director
Martin Wolpoff Director
Veronica Schwendemann Director
<PAGE>
DAXOR CORPORATION
Item 14(a) (1). Index to Financial Statements
The following statements and schedules of Daxor Corporation are submitted
herewith:
Page
Report of Independent Accountants................................... F-1
Financial Statements as at December 31, 1995 and 1994
and for the three years ended December 31, 1993
Balance Sheets.................................... F-2
Statements of Income.............................. F-3
Statements of Shareholders' Equity................ F-3
Statements of Cash Flows.......................... F-4
Notes to Financial Statements....................................... F-5
Schedule I - Marketable Securities - Other Investments - Year ended
December 31, 1995................................................. F-9
Schedule IX - Short-term Borrowings - Years ended December 31, 1995
1994, and 1993.................................................... F-9
Schedule X - Supplementary Income Statement Information -
Years ended December 31, 1995, 1994, and 1993....................... F-9
Exhibit - 27 Supplementary Exhibit as required by the
Securities And Exchange Commission..................... Exhibit 1
All other schedules for which provision is made in the applicable accounting
regulations of the Securities and Exchange Commission are not required under
the related instructions, are inapplicable or the required information is set
forth in the financial statements filed herewith, including notes thereto, and
therefore have been omitted.
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1
<S> <C>
<PERIOD-TYPE> 12-MOS
<FISCAL-YEAR-END> DEC-31-1995
<PERIOD-END> DEC-31-1995
<CASH> 1,987
<SECURITIES> 35,735,073
<RECEIVABLES> 409,196
<ALLOWANCES> 0
<INVENTORY> 158,000
<CURRENT-ASSETS> 37,290,135
<PP&E> 1,028,850
<DEPRECIATION> (606,180)
<TOTAL-ASSETS> 37,744,621
<CURRENT-LIABILITIES> 5,691,790
<BONDS> 0
0
0
<COMMON> 53,097
<OTHER-SE> 32,052,831
<TOTAL-LIABILITY-AND-EQUITY> 37,744,621
<SALES> 1,864,552
<TOTAL-REVENUES> 4,748,935
<CGS> 1,041,275
<TOTAL-COSTS> 3,296,962
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> (113,973)
<INCOME-PRETAX> 1,451,973
<INCOME-TAX> 164,858
<INCOME-CONTINUING> 1,287,115
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 1,287,115
<EPS-PRIMARY> 0.26
<EPS-DILUTED> 0.26
</TABLE>
